Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet

Shares of Mineralys Therapeutics, Inc. (MLYS) have gained 5.1% over the past four weeks to close the last trading session at $38.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.63 indicates a potential upside of 27.6%.The average comprises eight short-term price targets ranging from a low of $42.00 to a high of $56.00, with a standard deviation of $5.78. While the lowest ...